A Collaborative Study to Evaluate the Efficacy of Prospective Post-Induction Infliximab Dosing Based on Trough Levels at week 12 and 28 in Subjects with Crohn's Disease (CD) and Ulcerative Colitis (UC)

Trial Profile

A Collaborative Study to Evaluate the Efficacy of Prospective Post-Induction Infliximab Dosing Based on Trough Levels at week 12 and 28 in Subjects with Crohn's Disease (CD) and Ulcerative Colitis (UC)

Planning
Phase of Trial: Phase II

Latest Information Update: 27 Oct 2016

At a glance

  • Drugs Infliximab (Primary)
  • Indications Crohn's disease; Irritable bowel syndrome; Ulcerative colitis
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top